Short Bowel Syndrome Market Growth in Future Scope 2023-2030

The global Short Bowel Syndrome Market is estimated to be valued at US$ 7,310.1 Mn or Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Short bowel syndrome (SBS) is a condition that occurs when a significant portion of the small intestine is either surgically removed or non-functioning due to disease. The small intestine plays an important role in digestion and absorption of nutrients from food. When part of it is removed or not working, fewer nutrients and fluids can be absorbed into the body. People with SBS may require supplemental feeds through intravenous infusion (parenteral nutrition or IV feeding) or enteral nutrition (tube feeding) to get the nutrition they cannot absorb on their own from food. Treatment options for SBS include lifestyle changes, medications, surgical procedures, and enteral/parenteral nutrition support. The short bowel syndrome market comprises drugs and nutrition support which help in managing the symptoms and improving the intestinal absorption in patients suffering from SBS.

Market key trends:

One of the key trends in the short bowel syndrome market is the increasing demand for GLP-2 therapies. GLP-2 is a peptide produced by intestinal L-cells. It stimulates intestinal growth and repair, increases blood flow to the intestine and reduces inflammation. Some of the approved GLP-2 therapies include Teduglutide (Gattex) and Glepaglutide. Teduglutide is the first and only approved therapy for the treatment of short bowel syndrome. Its ability to promote intestinal adaptation has significantly improved the management of patients with SBS. Another key trend is the growing number of pipeline drugs targeting specific mechanisms to enhance intestinal adaptation in SBS patients. Some companies are developing therapies targeting FGF19/FGF21 and other related mechanisms. Overall, the availability of novel targeted therapies is expected to improve treatment outcomes and fuel market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The short bowel syndrome market requires high RD investments and regulatory approvals, thus posing a moderate threat of new entrants.
Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of alternative treatment options.
Bargaining power of suppliers: Suppliers have low bargaining power due to the presence of many raw material suppliers.
Threat of new substitutes: There is a low threat from substitutes as short bowel syndrome has limited treatment options.
Competitive rivalry: The competitive rivalry in the short bowel syndrome market is high due to the presence of key players.

Key Takeaways

The global Short Bowel Syndrome market is expected to witness high growth, exhibiting a CAGR of 5.5% over the forecast period, due to increasing research and development activities focusing on developing new treatment drugs.

On the regional front, North America is expected to dominate the global short bowel syndrome market over the forecast period. This is attributed to various factors such as the increasing prevalence of short bowel syndrome, rising healthcare expenditure, and growing research activities in the region. However, Asia Pacific is anticipated to exhibit the fastest growth during the forecast period.

Key players operating in the short bowel syndrome market include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V. These players are focusing on new product launches and geographical expansion to strengthen their presence in the market.